



# Local Delivery and Tissue Restricted Expression to Optimize Therapeutic Profile for Pancreatic Gene Therapy

Harith Rajagopalan, Jason A. West, Alice Liou, Rebecca Reese, Jacob Wainer, Nidhi Khanna, Suya Wang, Keiko Ishida, Nicole Picard, Camila Lubaczeuski, Emily Cozzi, Jay Caplan

May 18, 2023

## **Disclosure Statement**

**Authors:** Harith Rajagopalan, Jacob Wainer, Alice Liou, Rebecca Reese, Suya Wang, Keiko Ishida, Nicole Picard, Camila Lubaczeuski, Emily Cozzi, and Jay Caplan are employees and shareholders of Fractyl Health, Inc. Jason A. West and Nidhi Khanna are former employees of Fractyl Health, Inc. Christopher C. Thompson, Linda S. Lee, and Rob P. Trasolini are employees of Brigham and Women's Hospital and Harvard Medical School.

Revita<sup>®</sup> is for investigational use only in the United States. The Rejuva<sup>®</sup> platform is in early development and not approved by any regulatory body for investigational or commercial use.



# Fractyl Health, Inc.

Pioneering new treatment approaches for type 2 diabetes (T2D)


**Complementary development programs targeting key organs in T2D** 

## **Revita**<sup>®</sup> (targeting the duodenum)

Endoscopic procedure using hydrothermal ablation in the duodenum

**Rejuva**<sup>®</sup> (targeting the pancreas)


Adeno-associated virus (AAV)—based pancreatic gene therapy platform




# **Rejuva Directly Targets the Pancreas with Gene Therapy** Key therapeutic elements



**Endoscopic device** and procedure



AAV Gene Therapy Delivery Vehicle



**Tissue-Restricted Transgene Expression** 



# **Rationale for AAV-GLP1RA Gene Therapy to Improve Islet Function** Declining islet health is an early driver of T2D progression

T2D islet:


 $\beta$ -cell loss of insulin

Fractyl Health 2023

5

a-cell excess glucagon

GLP1RAs reverse both and improve islet cell health<sup>1</sup>





# **Rationale for AAV-GLP1RA Gene Therapy to Improve Islet Function** Declining islet health is an early driver of T2D progression


T2D islet:

 $\beta$ -cell loss of insulin

a-cell excess glucagon

GLP1RAs reverse both and improve islet cell health<sup>1</sup>

AAV-GLP1RA gene therapy may address limitations by driving local, durable production of GLP1RA to improve in islet function





# **EUS-Guided AAV ROA Feasibility in Yucatan Pig**

Porcine model approximates human GI tract and pancreas anatomy



\*AAV9-CMV-GFP used to assess on target efficacy and acute safety



# **EUS-Guided AAV ROA in Yucatan Pig**

Serum ALT and lipase remained in the normal range across most timepoints

A) 28-day ALT **B)** 7-day Lipase C) 28-day Lipase 70 80 70 60 60 Normal Range 60 50 3x ULN 50 3x ULN U/L 40 40 40 30 30 Normal Normal 20 Range 20 Range 20 10 10 0 0 3 5 7 7 14 21 28 0.5 1.0 14 21 28 0 0 0 Days Days Days 5.0e12 Vehicle 1.0e13 5.0e13 1.5e14




Mean  $\pm$  SEM shown; N=13, n=2-4 per group. ALT=alanine transaminase, EUS=endoscopic ultrasound, ROA=route of administration, AAV=adeno-associated virus

# **EUS-Guided AAV ROA in Yucatan Pig**

Dose-dependent expression of GFP throughout targeted splenic lobe

**5e13** 

## **A)** Extensive GFP in Splenic Lobe




**Connecting Lobe** 

Splenic Lobe

## **B)** VG Dose-Dependent GFP in Pancreas

R


03



1e13



1.5e14





9


EUS=endoscopic ultrasound, ROA=route of administration, AAV=adeno-associated virus, GFP=green fluorescent protein, VG=vector genomes

# **EUS-Guided AAV ROA in Yucatan Pig**

~ 40% of splenic lobe endocrine cells express GFP transgene at highest dose

**A)** Endocrine GFP Expression

**B)** On-target VCN




10 Fractyl Health 2023

Mean  $\pm$  SD shown; n=2-7 per group, EUS=endoscopic ultrasound, ROA=route of administration, AAV=adeno-associated virus, GFP=green fluorescent protein, VCN=vector copy number, VG=vector genomes, DG=diploid genomes

# **EUS-Guided AAV Route of Administration Feasibility in Yucatan Pig** Local vs. systemic delivery AAV biodistribution comparison

A) EUS (4.2e12 VG/kg)

**B) I.V.** (8.3e12 VG/kg, Li et al. 2022<sup>1</sup>)






11 Fractyl Health 2023

Figure adapted from 1. Li et al. Physiol Genomics 54: 261–272, 2022. EUS, N=4; I.V., N=2; EUS=endoscopic ultrasound, ROA=route of administration, AAV=adeno-associated virus, VCN=vector copy number, VG=vector genomes, DG=diploid genomes, I.V.=intravenous

# **EUS-Guided AAV Route of Administration Feasibility in Yucatan Pig**

AAV-GFP biodistribution unaffected by promotor restriction with highest VCN in pancreas





12 Fractyl Health 2023

Dose: 5e13 VG. N=2-4 per group; EUS=endoscopic ultrasound, ROA=route of administration, AAV=adeno-associated virus, GFP=green fluorescent protein, CMV=cytomegalovirus, INS=insulin, VG=vector genome, DG=diploid genome, VCN=vector copy number, SL=splenic lobe, DL=duodenal lobe, CL=connecting lobe

# **EUS-Guided AAV Route of Administration Feasibility in Yucatan Pig** Preliminary AAV-GFP toxicology findings segregated by promotor

Assessment	<b>AAV-INS-GFP</b> (β-cell Restricted, N=7)	<b>AAV-CMV-GFP</b> (Ubiquitous, N=11)
Clinical findings	None	(n=1) ataxia, mild hindlimb paresis, forelimb knuckling (day 24, 5e13 VG)
Clinical blood chemistries	No relevant changes	(n=1) transient elevation in lipase (< 3x ULN) on day 1; normalized by day 4
Hematology	No relevant changes	No relevant changes
Organ weight	No adverse organ weight changes	No adverse organ weight changes
Histopathology	No relevant findings	Minimal to moderate DRG inflammation (C2, T7, and L2 vertebrae)
Immune response	N/A	N/A



# **EUS-Guided AAV Route of Administration Feasibility in Yucatan Pig** Lipase elevation associated with GFP & abolished by promotor restriction


25



**Elevated lipase likely** related to pancreatic **GFP** expression

AAV-CMV-GFP

500 ur







n=2-4 per group; EUS=endoscopic ultrasound, ROA=route of administration, AAV=adeno-associated virus, GFP=green fluorescent protein, CMV=cytomegalovirus, INS=insulin, VG=vector genome


# **EUS-Guided AAV Route of Administration Feasibility in Yucatan Pig** AAV-GFP DRG toxicity is mitigated by promotor restriction

**AAV9-CMV-GFP Inflammation, GFP expression** 




AAV9-INS-GFP No inflammation, no GFP expression







# NF-L Appears to be a Good Biomarker for DRG Toxicity Dose-dependent increases with AAV-CMV but no signal with AAV-INS AAV-CMV-GFP NF-L B) AAV-CMV-GFP vs AAV-INS-GFP NF-L



N=7, n=2-4 per group; AAV=adeno-associated virus, GFP=green fluorescent protein, CMV=cytomegalovirus, INS=insulin, NF-L=neurofilament light chain




## Conclusions

Local AAV9 via EUS shows on target gene expression with low viral dose

Favorable biodistribution profile to the pancreas compared to other tissues.

The pig model is a very useful and sensitive model for tox assessment.

Mechanical and molecular confinement of transgene expression thus far appear to optimize therapeutic index





# **Thank You For Your Attention** Acknowledgements

## **Fractyl Health**

### **Cell and Animal Models**







Alice Liou Fitzpatrick

Camila Lubaczeuski

Becky Reese

#### Nicole Picard

**Virus and Gene Delivery** 





#### Gary White Suya Wang



Keiko Ishida



## **External Support**

**SBH Sciences:** Michael Furniss, Beth Griffith, Gerard O'Neil for conducting cell and islet work

## Joslin Diabetes Center Islet Isolation Core: Jennifer Hollister-Lock for technical advice and sourcing mouse islets

Human Cell Design: Bruno Blanchi for sourcing EndoC-BH5 cells

**InSphero AG:** Sayro Jawurek, Alexandra Title, Maria Karsai for the human islets microtissue experiments

**ERASE Task Force:** Randy Seeley, PhD (Michigan School of Medicine) and Alan Cherrington, PhD (Vanderbilt University School of Medicine) for scientific expertise and data interpretation







Jake Wainer Mike Biasella Fractvl Health 2023 18